Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Lancet · 2026-10-26

In 498 patients in China with EGFR-mutated advanced NSCLC progressing after EGFR-TKI therapy, the HER3-directed antibody-drug conjugate ruzaltatug rezetecan improved PFS vs platinum–pemetrexed (median 8·3 vs 5·4 months; HR 0·47) at interim analysis.

RCTn = 498
Xu et al. Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China
Oncology · Lancet Oncol · 2026-09-11

In a post hoc analysis of a stepped-wedge cluster trial of 446 patients with stage I–IV lung cancer, weekly online symptom reporting vs usual care had median overall survival of 26 vs 21 months (adjusted HR 0·80, 95% CI 0·63–1·00); progression-free survival did not differ.

Secondary analysisn = 446
Hassing et al. Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial
Oncology · Lancet · 2026-09-06

In patients with high-risk, inoperable early-stage NSCLC, adding atezolizumab to SBRT did not improve overall survival vs SBRT alone (HR 1.04; 2-year OS 82% in both groups). The trial closed for futility. Grade ≥3 adverse events were 12% vs 3%.

RCTn = 417
Daly et al. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial
Oncology · Lancet Oncol · 2026-09-01

Secondary analysis of ALINA (257 patients, resected ALK-positive NSCLC): adjuvant alectinib vs platinum chemotherapy gave fewer serious treatment-related adverse events (2% vs 7%) and discontinuations (5% vs 13%); quality of life on alectinib improved (exploratory).

Secondary analysisn = 257
Dziadziuszko et al. Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial
Oncology · Lancet Oncol · 2026-09-01

In 438 patients with EGFR-mutated NSCLC progressing on third-generation EGFR TKIs, ivonescimab plus chemotherapy lengthened median PFS vs placebo plus chemotherapy (6·8 vs 4·4 months; HR 0·52); overall survival gain was not significant (HR 0·79; 95% CI 0·62–1·01).

RCTn = 438
Le et al. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.